Brief: Bayer - European Medicines Agency Confirms Asundexian Marketing Authorization Application For Assessment In Secondary Prevention Of Ischemic Stroke
10/06/2026 07:32
BRIEF-Bayer - European Medicines Agency Confirms Asundexian Marketing Authorization Application For Assessment In Secondary Prevention Of Ischemic Stroke June 10 (Reuters) - BAYER AG BAYGn.DE:
EUROPEAN MEDICINES AGENCY CONFIRMS ASUNDEXIAN MARKETING AUTHORIZATION APPLICATION FOR ASSESSMENT IN SECONDARY PREVENTION OF ISCHEMIC STROKE
VALIDATION OF THE APPLICATION CONFIRMS THE SUBMISSION IS COMPLETE AND BEGINS THE EMA’S CENTRALIZED REVIEW PROCEDURE
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women